Hypoxia-Regulated Gene Therapy Vector for Ocular Neovascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), diabetic retinopathy, and retinopathy of prematurity are inadequate, often requiring costly and invasive procedures with potential side effects, and there is a need for more effective methods to prevent or treat pathological proliferation of blood vessels in the eye.
Innovation Solution
A gene therapy approach using a hypoxia-regulated, retinal pigment epithelial cell-specific vector to produce angiogenesis-inhibiting proteins like endostatin only in pathological areas, reducing neovascularization while minimizing impact on normal vessels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments (injections, laser photocoagulation) are used to treat pathological neovascularization, then neovascularization is inhibited, but the treatments are invasive, costly, and may cause infection or damage to normal vessels
Solution Approach 1:
The patent applies local quality by using a retinal pigment epithelial cell-specific vector that selectively expresses endostatin only in the RPE layer at the site of pathological neovascularization. This localized expression inhibits neovascularization in the affected area while sparing normal vessels throughout the rest of the retina, thus resolving the contradiction between effectiveness and harm to normal tissue.
Solution Approach 2:
The patent employs self-service by utilizing the body's own RPE cells to produce the therapeutic agent endostatin through the viral vector. The endogenous RPE cells take up the vector and autonomously express the anti-angiogenic protein, eliminating the need for external injections or surgical interventions, thereby reducing invasiveness while maintaining treatment effectiveness.
2Reliability
If constant production of anti-angiogenic agents is used, then neovascularization is continuously inhibited, but long-term deleterious effects on normal vessels may occur
Solution Approach 1:
The patent applies dynamics by creating a conditional expression system where the vector remains silent under normal oxygen conditions but activates specifically under hypoxic conditions that trigger neovascularization. This dynamic, conditionally activated expression ensures continuous inhibition of neovascularization when needed while avoiding constant production that would harm normal vessels.
Solution Approach 2:
The patent converts the harmful hypoxic environment that drives neovascularization into a beneficial activation signal for the therapeutic gene. The hypoxia-responsive element uses the body's own hypoxic stress signal to trigger endostatin production, turning the harmful condition into the precise moment when treatment is most needed, thereby inhibiting neovascularization without affecting normal oxygenated tissue.
3Reliability
If multiple injections are administered to treat ocular neovascularization, then treatment effectiveness is improved, but cost and risk of infection increase
Solution Approach 1:
The patent applies preliminary action by administering the viral vector a single time before neovascularization fully develops. The vector establishes long-term expression of endostatin in RPE cells, providing continuous protection against neovascularization without requiring repeated injections. This single preliminary administration prevents the need for multiple subsequent treatments and reduces cumulative infection risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively inhibits pathological ocular neovascularization, offering a more targeted and less invasive treatment option with improved outcomes compared to traditional therapies, reducing the area of choroidal neovascularization by up to 80% and providing conditional expression of endostatin to prevent long-term deleterious effects on normal vessels.
Implementation Method 1
a hypoxia-regulated, retinal pigment epithelial cell-specific vector to produce angiogenesis-inhibiting proteins like endostatin only in pathological areas
Data Source
AI summary
The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.